Information  X 
Enter a valid email address

LiDCO Group Plc (LID)

  Print      Mail a friend       Annual reports

Tuesday 12 March, 2019

LiDCO Group Plc

Master distribution agreement for Latin America

RNS Number : 5147S
LiDCO Group Plc
12 March 2019
 

LiDCO Group Plc

("LiDCO" or the "Company")

 

Master distribution agreement for Latin America

 

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has signed a master distribution agreement for LiDCO products with Brazil based Elysian Fields Medical ('Elysian Fields') covering a number of territories across Latin America.

 

This agreement, which initially runs for two years, covers all the major countries in Latin America including Brazil, Mexico, Argentina, Chile, Uruguay, Peru, Columbia and Paraguay. Elysian Fields will actively promote the LiDCO product range and take responsibility for distributor management in those countries, as well as undertake the co-ordination of regulatory and registration requirements needed in each territory.

 

Elysian Fields' management team has extensive experience with hemodynamic monitoring in the region, having previously worked for Edwards Lifesciences, the global market leader.

 

Hemodynamic monitoring is an established concept in the larger South American countries, with LiDCO management estimating that the entire region represents up to 10% of current global demand. LiDCO expects to register its latest monitor in Brazil and Columbia during 2019 and the Company will work with Elysian Fields to prioritise other market registrations. LiDCO will look to launch its differentiated High Usage Programme in selected markets where appropriate.

 

Commenting Matt Sassone, Chief Executive Officer, said: "Driving geographical expansion from our core UK home market is a key driver of future growth for LiDCO and accordingly we continue to expand our distribution network globally. To date LiDCO hasn't historically focused on Latin America, hence we are delighted to be partnering with Elysian Fields, given their expert knowledge of the hemodynamic monitoring market in this region."

 

For further information, please contact:

 

LiDCO Group Plc

www.lidco.com

Matt Sassone (CEO)

Tel: +44 (0)20 7749 1500



finnCap

Tel: +44 (0)20 7600 1658

Geoff Nash / Emily Watts / Hannah Boros (Corporate Finance)


Andrew Burdis (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

 

A number of clinical studies have shown that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

 

Key Products:

 

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

 

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

 

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:

 

·     early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·     quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

 

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

 

*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.

 

LiDCO monitors use single-patient disposables (sensors or smartcards) and are also available in many markets as a software for service model all of which provide a recurring revenue stream. 

 

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

 

LiDCO's headquarters are in London and its shares are traded on AIM.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGRSFAFWFFUSELD

a d v e r t i s e m e n t